Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of (R,R)-Tramadol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 8/20 | 0.66 |
| ▸ | SLC6A2 | P23975 | 9/20 | 0.66 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.66 |
| ▸ | OPRD1 | P41143 | 7/20 | 0.66 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.66 |
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.66 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.66 |
| ▸ | HTR3A | P46098 | 2/20 | 0.48 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (R,R)-Tramadol SCHEMBL14320250 | 0.99 | SLC6A2 (0.65) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL2678948 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Tramadol SCHEMBL4799725 | 0.92 | SLC6A2 (0.76) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL18171987 | 0.90 | SLC6A2 (0.71) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Isalmadol SCHEMBL5534029 | 0.88 | SLC6A2 (0.66) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Isalmadol SCHEMBL29711375 | 0.88 | SLC6A2 (0.66) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| Isalmadol SCHEMBL6437705 | 0.88 | SLC6A2 (0.66) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| (R,R)-Tramadol SCHEMBL2678627 | 0.88 | SLC6A2 (0.82) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL29965897 | 0.85 | SLC6A2 (0.73) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 | |
| SCHEMBL28004517 | 0.85 | SLC6A2 (0.73) | SLC6A2SLC6A4OPRM1OPRD1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130072470-A1 | NOVEL TRICYCLIC COMPOUNDS | ABBVIE INC. (US) | 2013-03-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130072470-A1 | NOVEL TRICYCLIC COMPOUNDS | CYP11B2, CYP11B1, ABCB1 | OPRM1 357/4885SLC6A2 1111/4885SLC6A4 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.